About this episode
More and more vaccines are getting authorization in the United States to prevent COVID-19. However, sometimes a vaccine trial is not always effective. But even failure can provide new insights. Learn about the Janssen COVID-19 vaccine and what happened with the recent Hepatitis C vaccine candidate. This podcast was recorded prior to the joint CDC and FDA statement on the Johnson & Johnson/Janssen COVID-19 vaccine on April 13th. On April 13th, 2021, the CDC and FDA issued a joint statement recommending a pause on the use of the Johnson & Johnson/Janssen COVID-19 vaccine until further notice. Click here for the full statement. Reference: Page K, Melia M, Veenhuis R, et al. Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection. N Engl J Med 2021; 384:541-549. DOI: 10.1056/NEJMoa2023345 Fact Sheet for Healthcare Providers Administering Vaccine Emergency Use Authorization of the Janssen COVID-19 Vaccine to Prevent Coronavirus Disease 2019. https://www.fda.gov/media/146304/download CPE details for GameChangers Podcast April 2021 Learning Objective: Describe the outcomes of a recently published trial on hepatitis C vaccine candidates. 0107-0000-21-158-H01-P 0.2 CEU/2 Hrs (Knowledge) Initial Release Date: 04/06/21 Expiration Date: 03/02/24 Additional CPE information is located at https://www.ceimpact.com/podcast See omnystudio.com/listener for privacy information. Learn more about your ad choices. Visit megaphone.fm/adchoices